Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
S Das, DB Johnson - Journal for immunotherapy of cancer, 2019 - Springer
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …
[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors
Background Adults with impaired performance status (PS) often receive immune checkpoint
inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy …
inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy …
Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
Immune‐related adverse events (IrAEs) of immune checkpoint inhibitors (ICIs) can be
serious and unpredictable. We examine the incidence rate and risk factors for IrAEs in an …
serious and unpredictable. We examine the incidence rate and risk factors for IrAEs in an …
[HTML][HTML] Efficacy and immune-related adverse event associations in avelumab-treated patients
Background Adverse events (AEs) of special interest that arise during treatment with
immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to …
immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to …
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis
Y Zhou, H Chen, L Tang, Y Feng, Y Tao, L Huang… - …, 2023 - Taylor & Francis
Aim: This study aimed to explore the association of immune-related adverse events (irAEs)
with efficacy in advanced non-small-cell lung cancer (NSCLC). Materials & methods: A …
with efficacy in advanced non-small-cell lung cancer (NSCLC). Materials & methods: A …
[PDF][PDF] Immune-related adverse events and outcomes in patients with advanced non–small cell lung cancer: a predictive marker of efficacy?
Dr. Reguart reports personal fees from MSD, personal fees from Bristol-Myers, personal fees
from Roche, personal fees from Boehringer Ingelheim, personal fees from Guardant Health …
from Roche, personal fees from Boehringer Ingelheim, personal fees from Guardant Health …
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
J Remon, L Esteller, Á Taus - Cancer Management and Research, 2019 - Taylor & Francis
Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in
combination with chemotherapy have become the standard of care in the first-line treatment …
combination with chemotherapy have become the standard of care in the first-line treatment …
Les avancées dans la prise en charge des cancers bronchopulmonaires: ce qui change pour le réanimateur
J Pinsolle, N Terzi, L Ferrer, MG Levra… - Médecine Intensive …, 2019 - revue-mir.srlf.org
Résumé Le cancer bronchopulmonaire (CBP) est la première cause de mortalité par cancer
en France et dans le monde, mais son pronostic tend à s' améliorer depuis une dizaine …
en France et dans le monde, mais son pronostic tend à s' améliorer depuis une dizaine …
[CITATION][C] Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Á Taus García, J Remon, L Esteller - 2019 - Dove Medical Press